NeurologyLive® Friday 5 — April 28, 2023

Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 28, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: NeurologyLive® and CMSC Announce Giants of Multiple Sclerosis® 2023 Class of Inductees

Giants of Multiple Sclerosis is a premier neuroscience award that celebrates pioneers, innovators, and difference makers who have been selected by their peers for their remarkable achievements in multiple sclerosis.

NeurologyLive® and CMSC Announce Giants of Multiple Sclerosis® 2023 Class of Inductees

2: Peer Exchange: Diagnosis of Narcolepsy

In episode 4 of this Peer Exchange series on "Advances in the Management of Excessive Daytime Sleepiness and Narcolepsy", experts discuss narcolepsy diagnosis and the challenges associated with it.

Diagnosis of Narcolepsy

3: NeuroVoices: John Greenfield, MD, PhD, on the Growth of Neurology and the Budding Young Community of Neurologists

In the latest edition of our in-depth Q&A series, the president elect of the Association of University Professors of Neurology provided thoughts on the promising concepts in neurology and the reasons young medical professionals should join the field.

NeuroVoices: John Greenfield, MD, PhD, on the Growth of Neurology and the Budding Young Community of Neurologists

4: Special Episode: Tofersen Approved for SOD1 Amyotrophic Lateral Sclerosis

This episode, "Tofersen Approved for SOD1 Amyotrophic Lateral Sclerosis," features an exclusive interview with Angela Genge, MD, FRCPC, the director of the ALS Centre of Excellence for Research and Patient Care at McGill University, and an executive at the Clinical Research Unit at The Neuro (Montreal Neurological Institute-Hospital). [LISTEN TIME: 13 minutes]

Special Episode: Tofersen Approved for SOD1 Amyotrophic Lateral Sclerosis

5: Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc
Related Videos
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.